ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Current share price.

<< Previous

Bullboard Posts

Next >>

Post by garygpon Jul 16, 2021 1:27pm

158 Views

Post# 33560255

Current share price.

Just thinking out loud, but at 18.5 cents and anything lower during the summer, I believe this could be a real opportunity for both new and current shareholders to reposition themselves and add to current holdings during the summer doldrums.

Seems to me that here and lower is a gift.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023